Anita Kumar is an Oncology physician. ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1275 York Ave
New York, NY 100656007
Telephone
212-639-3850Registry record last updated 8 Aug 2014.
Clinical trials
- A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
- MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)
Sponsor: George Washington University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- BeOne Medicines USA, Inc.Program year20252 payments
- Genentech USA, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
45.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor45.2%Acyclovir100%Part D≥60 patientsCancer & immunology
24.8%Kinase inhibitor19.7%Brukinsa79%Imbruvica21%Part D<11 patientsBCL-2 Inhibitor3.2%Venclexta100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
19.9%Proton pump inhibitor12.1%Pantoprazole Sodium100%Part D≥24 patientsCorticosteroid7.8%Prednisone100%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”